Clay B. Thorp's most recent trade in Clearside Biomedical Inc was a trade of 15,000 Common Stock done at an average price of $0.9 . Disclosure was reported to the exchange on Feb. 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Clearside Biomedical Inc | Clay B. Thorp | Director | Purchase of securities on an exchange or from another person at price $ 0.92 per share. | 24 Feb 2025 | 15,000 | 176,141 (0%) | 0% | 0.9 | 13,800 | Common Stock |
| Clearside Biomedical Inc | Clay B. Thorp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Clearside Biomedical Inc | Clay B. Thorp | Director | Purchase of securities on an exchange or from another person at price $ 1.02 per share. | 21 Dec 2022 | 14,000 | 30,522 (0%) | 0% | 1.0 | 14,266 | Common Stock |
| Clearside Biomedical Inc | Clay B. Thorp | Director | Other type of transaction at price $ 0.00 per share. | 15 Dec 2022 | 1,406,507 | 3,545,040 (7%) | 3% | 0 | Common Stock | |
| Clearside Biomedical Inc | Clay B. Thorp | Director | Other type of transaction at price $ 0.00 per share. | 15 Dec 2022 | 8,522 | 16,522 (0%) | 0% | 0 | Common Stock | |
| Clearside Biomedical Inc | Clay B. Thorp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Vigil Neuroscience Inc | Clay B. Thorp | Director | Purchase of securities on an exchange or from another person at price $ 2.76 per share. | 16 May 2022 | 21,802 | 1,541,137 | - | 2.8 | 60,221 | Common Stock |
| Vigil Neuroscience Inc | Clay B. Thorp | Director | Purchase of securities on an exchange or from another person at price $ 2.97 per share. | 16 May 2022 | 14,893 | 1,556,030 | - | 3.0 | 44,189 | Common Stock |
| Vigil Neuroscience Inc | Clay B. Thorp | Director | Purchase of securities on an exchange or from another person at price $ 7.20 per share. | 28 Mar 2022 | 3,000 | 3,000 | - | 7.2 | 21,604 | Common Stock |
| Vigil Neuroscience Inc | Clay B. Thorp | Director | 11 Jan 2022 | 2,552,021 | 0 | - | - | Series A Preferred Stock | ||
| Vigil Neuroscience Inc | Clay B. Thorp | Director | 11 Jan 2022 | 1,254,335 | 1,254,335 | - | - | Common Stock | ||
| Vigil Neuroscience Inc | Clay B. Thorp | Director | 11 Jan 2022 | 926,506 | 0 | - | - | Series B Preferred Stock | ||
| Vigil Neuroscience Inc | Clay B. Thorp | Director | Purchase of securities on an exchange or from another person at price $ 14.00 per share. | 11 Jan 2022 | 265,000 | 1,519,335 | - | 14 | 3,710,000 | Common Stock |
| Clearside Biomedical Inc | Clay B. Thorp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Clearside Biomedical Inc | Clay B. Thorp | Director | Sale of securities on an exchange or to another person at price $ 4.43 per share. | 10 Feb 2021 | 32,873 | 4,951,547 (11%) | 0% | 4.4 | 145,627 | Common Stock |
| Clearside Biomedical Inc | Clay B. Thorp | Director | Sale of securities on an exchange or to another person at price $ 4.43 per share. | 10 Feb 2021 | 32,873 | 3,433,521 (7%) | 0% | 4.4 | 145,627 | Common Stock |